UBS Group Forecasts Strong Price Appreciation for Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective boosted by analysts at UBS Group from $36.00 to $42.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 20.01% from the company’s current price.

A number of other equities analysts also recently weighed in on the stock. Truist Financial lifted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday. The Goldman Sachs Group lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Finally, Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $41.56.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $35.00 on Thursday. Teva Pharmaceutical Industries has a twelve month low of $14.99 and a twelve month high of $37.35. The firm has a fifty day simple moving average of $31.15 and a 200 day simple moving average of $29.33. The company has a market capitalization of $40.24 billion, a PE ratio of 26.31, a P/E/G ratio of 3.09 and a beta of 0.76. The company has a quick ratio of 0.80, a current ratio of 1.01 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $3.98 billion during the quarter. On average, sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.6 EPS for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total value of $1,871,754.28. Following the completion of the sale, the insider directly owned 224,940 shares of the company’s stock, valued at approximately $6,779,691.60. The trade was a 21.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian Savage sold 1,127 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the sale, the insider directly owned 10,914 shares of the company’s stock, valued at approximately $345,646.38. This trade represents a 9.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 920,901 shares of company stock valued at $30,056,789. 0.54% of the stock is owned by insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Norges Bank bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after acquiring an additional 7,255,083 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Teva Pharmaceutical Industries by 39,228.4% during the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock worth $139,296,000 after acquiring an additional 6,878,304 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Teva Pharmaceutical Industries by 18.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after acquiring an additional 5,917,423 shares in the last quarter. Finally, Schroder Investment Management Group increased its position in shares of Teva Pharmaceutical Industries by 261.1% during the fourth quarter. Schroder Investment Management Group now owns 7,426,885 shares of the company’s stock worth $231,793,000 after acquiring an additional 5,370,253 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 earnings beat and revenue upside driven by branded products (Austedo, Ajovy, Uzedy), which lifted investor sentiment and underpins near?term earnings growth. Read More.
• Positive Sentiment: Multiple broker upgrades and higher price targets — UBS, Truist, JPMorgan and Piper Sandler raised targets/ratings over the last day, signaling analyst confidence in a re?rating and further upside for the stock. Read More. Read More.
• Positive Sentiment: Teva agreed to acquire Emalex for ~\$900M to add ecopipam (paediatric Tourette’s) — a late?stage, de?risked asset that bolsters the specialty/innovative portfolio and supports the narrative that Teva is shifting toward higher?margin branded growth. Read More.
• Neutral Sentiment: Teva published its 2025 Healthy Future Report and says it met all sustainability?linked bond targets — positive for ESG profile and potentially credit metrics, but unlikely to move near?term revenues. Read More.
• Neutral Sentiment: Blackstone put significant financing behind Teva in a recent deal — signals institutional interest/validation but primarily affects capital structure and optionality rather than immediate EPS. Read More.
• Neutral Sentiment: Industry reports list Teva among leaders in oral solid dosage contract manufacturing — positive for long?term service demand exposure but not an immediate earnings catalyst. Read More.
• Negative Sentiment: Generics revenue remains weak even as branded sales grow — raises questions about sustainability of overall top?line growth if branded momentum slows. Read More.
• Negative Sentiment: After a rapid share run?up, some analysts and coverage pieces note valuation/volatility risk — investors should weigh near?term upside from upgrades against stretched multiples and execution risk. Read More.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.